Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Modified-Release Drug Delivery Systems: Overview

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

Modified-Release Drug Delivery Systems: Influencing Factors

Modified-Release Drug Delivery Systems: Influencing Factors

Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...

Modified-Release Drug Delivery Systems: Rate-Programmed I

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Beyond conventional lithium-ion: anode-free lithium metal batteries for ultra-high energy and greener storage solutions.

RSC advances·2026

Same author

Properties of Probiotic Bacterial Cellulose/κ-Carrageenan Based Hydrogel Having Antibacterial Activity and Biocompatibility.

Gels (Basel, Switzerland)·2026

Same author

Tuft dendrites in frontal motor cortex enable flexible learning.

Science (New York, N.Y.)·2026

Same author

Asymmetric Supercapacitor Based on Biomass-Derived Carbon Electrodes Functionalized with NdFeB.

Materials (Basel, Switzerland)·2026

Same author

Regional variations in environmental impacts of NMC 811 production: Comparative LCA study across Visegrad countries.

iScience·2026

Same author

Ni- and Zn-Doping Effects on Cu/SiO<sub>2</sub> Catalysts in Nonoxidative Ethanol Dehydrogenation.

Industrial & engineering chemistry research·2026

Search research articles

Related Experiment Video

Updated: Jun 28, 2026

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs

Published on: December 9, 2010

Nanoparticle-Based Rifampicin Delivery System Development.

Marjan Motiei¹, Luis Pleno de Gouveia², Tomáš Šopík¹

¹Centre of Polymer Systems, University Institute, TBU, tr. Tomase Bati 5678, 76001 Zlin, Czech Republic.

Molecules (Basel, Switzerland)

|April 30, 2021

Summary

Developing novel polyelectrolyte nanoparticles (PENs) and using antioxidants can protect rifampicin from degradation in alkaline chronic wound environments. This approach enhances antibiotic stability and therapeutic potential.

Keywords:

alkaline pH ascorbic acid polyelectrolyte nanoparticles rifampicin

More Related Videos

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

Related Experiment Videos

Last Updated: Jun 28, 2026

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs

Published on: December 9, 2010

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

Area of Science:

Biomaterials Science
Drug Delivery Systems
Wound Healing Research

Background:

The alkaline conditions in chronic wounds compromise antibiotic efficacy, necessitating innovative drug delivery strategies.
Rifampicin's therapeutic effect is diminished in alkaline environments, highlighting the need for protective measures.

Purpose of the Study:

To synthesize and characterize novel polyelectrolyte nanoparticles (PENs) for drug delivery at alkaline pH.
To evaluate the synergistic effect of PENs and antioxidants on rifampicin stability and release in simulated wound conditions.

Main Methods:

Synthesis of two types of PENs with chitosan core and polycationic shell at alkaline pH.
Comprehensive physicochemical characterization using techniques like NMR, FT-IR, XRD, DSC, DLS, SEM, TEM, UV/Vis, and HPLC.
In vitro assessment of rifampicin release and degradation in the presence of PENs and ascorbic acid at different pH values (7.4 and 8.5).

Main Results:

Successfully synthesized PENs with distinct morphologies but similar physicochemical properties and release kinetics.
Demonstrated that PENs combined with ascorbic acid exhibit a synergistic protective effect on rifampicin degradation at alkaline pH (8.5) compared to neutral pH (7.4).

Conclusions:

Polyelectrolyte nanoparticles offer a promising platform for stabilizing antibiotics like rifampicin in alkaline wound environments.
The co-administration of PENs and antioxidants represents an effective strategy to mitigate antibiotic degradation and enhance therapeutic outcomes in chronic wounds.